Volume 17, Issue 5, Pages 600-611 (May 2016) Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study  Prof François Bertucci, MD, Mahmoud Fekih, MD, Aurélie Autret, MSc, Prof Thierry Petit, MD, Florence Dalenc, MD, Christelle Levy, MD, Gilles Romieu, MD, Prof Jacques Bonneterre, MD, Prof Jean-Marc Ferrero, MD, Prof Pierre Kerbrat, MD, Patrick Soulie, MD, Marie-Ange Mouret-Reynier, MD, Thomas Bachelot, MD, Florence Lerebours, MD, Jean-Christophe Eymard, MD, Mathilde Deblock, MD, Alain Lortholary, MD, Anne-Claire Hardy-Bessard, MD, Philippe Barthelemy, MD, Prof Hervé Bonnefoi, MD, Prof Emmanuelle Charafe- Jauffret, MD, François-Clément Bidard, MD, Prof Patrice Viens, MD, Jérôme Lemonnier, PhD, Prof Jean-Yves Pierga, MD  The Lancet Oncology  Volume 17, Issue 5, Pages 600-611 (May 2016) DOI: 10.1016/S1470-2045(16)00011-5 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Study design Dotted line on the box under radiotherapy, which represents bevacizumab, shows that bevacizumab could be restarted during (concomitant) or after (sequential) radiotherapy once wound healing was complete. The Lancet Oncology 2016 17, 600-611DOI: (10.1016/S1470-2045(16)00011-5) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Trial profile *Screening failures were not recorded. †These five patients were among the 18 who permanently discontinued neoadjuvant bevacizumab. The Lancet Oncology 2016 17, 600-611DOI: (10.1016/S1470-2045(16)00011-5) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 3 Disease-free survival and overall survival Kaplan-Meier curves for disease-free survival (A) and overall survival (B). Number at risk is shown as 0 at 60 months because data are not yet available for this timepoint. The Lancet Oncology 2016 17, 600-611DOI: (10.1016/S1470-2045(16)00011-5) Copyright © 2016 Elsevier Ltd Terms and Conditions